Adamis sends letter to stockholders regarding its strategic focus on tempol as a potentially potent treatment for covid-19

San diego--(business wire)--adamis pharmaceuticals corporation (nasdaq: admp) today issued the below letter to stockholders. june 28, 2021 dear stockholder, the board of directors (the "board") appreciates your continued investment in adamis pharmaceuticals corporation ("adamis" or the "company"). ahead of our annual meeting of stockholders on july 16th (the "annual meeting"), we want to once again urge you to vote to re-elect all five members of the board. we believe maintaining continuity in
ADMP Ratings Summary
ADMP Quant Ranking